Analysts at BMO Capital Markets assumed coverage on shares of VBI Vaccines, Inc. (NASDAQ:VBIV) in a report released on Wednesday. The firm set an “outperform” rating on the biopharmaceutical company’s stock.
A number of other research analysts also recently issued reports on VBIV. Noble Financial reaffirmed a “buy” rating on shares of VBI Vaccines in a research report on Monday, July 31st. Zacks Investment Research downgraded shares of VBI Vaccines from a “hold” rating to a “sell” rating in a research report on Tuesday, August 1st. ValuEngine downgraded shares of VBI Vaccines from a “hold” rating to a “sell” rating in a research report on Thursday, August 3rd. Finally, Canaccord Genuity assumed coverage on shares of VBI Vaccines in a research note on Wednesday, November 1st. They issued a “buy” rating and a $10.00 target price for the company. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the stock. VBI Vaccines has an average rating of “Hold” and a consensus target price of $10.00.
VBI Vaccines (NASDAQ VBIV) opened at $4.17 on Wednesday. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.91 and a current ratio of 2.00. VBI Vaccines has a 12-month low of $2.81 and a 12-month high of $6.60.
WARNING: This article was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The original version of this article can be accessed at https://www.dispatchtribunal.com/2017/11/15/vbi-vaccines-inc-vbiv-earns-outperform-rating-from-analysts-at-bmo-capital-markets.html.
In related news, CEO Jeff Baxter bought 10,000 shares of the stock in a transaction that occurred on Monday, August 21st. The stock was bought at an average cost of $3.22 per share, for a total transaction of $32,200.00. Following the purchase, the chief executive officer now directly owns 120,255 shares of the company’s stock, valued at $387,221.10. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Opko Health, Inc. bought 655,738 shares of the stock in a transaction that occurred on Monday, October 30th. The stock was bought at an average price of $3.05 per share, with a total value of $2,000,000.90. The disclosure for this purchase can be found here. Insiders purchased a total of 4,068,738 shares of company stock valued at $12,411,711 over the last quarter. 34.10% of the stock is owned by company insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in VBIV. California State Teachers Retirement System acquired a new stake in VBI Vaccines during the 2nd quarter valued at approximately $167,000. Schwab Charles Investment Management Inc. acquired a new stake in VBI Vaccines during the 2nd quarter valued at approximately $187,000. Bank of New York Mellon Corp acquired a new stake in VBI Vaccines during the 2nd quarter valued at approximately $193,000. Teachers Advisors LLC acquired a new stake in VBI Vaccines during the 2nd quarter valued at approximately $195,000. Finally, TIAA CREF Investment Management LLC acquired a new stake in VBI Vaccines during the 2nd quarter valued at approximately $262,000. Institutional investors and hedge funds own 20.38% of the company’s stock.
VBI Vaccines Company Profile
VBI Vaccines Inc, formerly SciVac Therapeutics Inc, is a biotechnology company. The Company is engaged in developing various technologies that focus on vaccine protection. It has developed an enveloped virus like particle (eVLP) vaccine platform that allows for the design of enveloped VLP vaccines. It is involved in various projects related to human cytomegalovirus (CMV) and other antigens.
Receive News & Ratings for VBI Vaccines Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines Inc. and related companies with MarketBeat.com's FREE daily email newsletter.